Abstract Library

#4477 Stable tumoural response to stereotactic body radiotherapy in well-differentiated metastatic small intestine neuroendocrine tumour

Introduction: Over half of patients with Neuroendocrine tumours (NET) have unresectable or metastatic disease. SSA y PRRT are successful targeted therapy to symptoms relief and stabilise disease. Otherwise, there are emerging options of radiotherapy including hypofractionation or stereotactic body radiotherapy. The clinical evidence of radiotherapy in NEN is scarce, and there is limited published data.

Conference:

Presenting Author: Florez A

Authors: Sanabria D, Florez A,

Keywords: Neuroendocrine, Tumour, metastatic,

#4407 Characterisation of patients with neuroendocrine tumours in a specialised care institution in oncological endocrinology Bogotá, Colombia

Introduction: Neuroendocrine tumours (NETs) are heterogeneous malignancies that arise from the diffuse neuroendocrine system. Its incidence has increased in the last 3 decades. They have a relatively indolent growth rate and are capable of secreting peptide hormones and biogenic amines.

Conference:

Presenting Author: Florez A

Authors: Rueda M, Florez A, Luna F, Fuentes O, Lizarazo D,

Keywords: Neuroendocrine tumour,

#4247 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia - A case report

Introduction: Idiopathic Diffuse Neuroendocrine Diffuse Neuroendocrine Hyperplasia is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women, Of available therapies, somatostatin analogs and mTOR are the most promising

Conference:

Presenting Author: Florez A

Authors: Florez A, Unigarro M, Fernandez J, Viola L, Perez G,

Keywords: neuroendocrine tumor, lung, idiopathic diffuse neuroendocrine hyperplasia, tumorlets,

#4030 Neuroendocrine tumors in pediatrics and young adults

Introduction: Neuroendocrine tumors (NETs) are rare and heterogeneous neoplasms with different origins, biology, hormone secretion, and genetic mutations. An increase in the presentation of NETs has been observed in

Conference:

Presenting Author:

Authors: González-Devia D, Andrade-Andrade P, Segovia-Gómez J, Florez-Romero A, Lopez-Panqueva R,

Keywords: Neuroendocrine Tumor, Neuroendocrine Neoplasm, Young people, Epidemiology, Neuroendocrine carcinoma,

#3764 Therapeutic response of ACTH-dependent ectopic Cushing's syndrome to low doses of osilodrostat

Introduction: Cushing's disease (CD) is the main cause of ACTH-dependent Cushing's syndrome (ACTH-CS). In 5–15% of cases, ACTH/CRH production is ectopic and is caused by neuroendocrine tumors of the lung, thymus, or pancreas, medullary thyroid carcinoma, and pheochromocytoma. Diagnostic imaging can locate the primary tumor; however, between 8-22% the cause is unknown. The FDA approved Osilodrostat for the treatment of inoperable or refractory CD, its use in high doses in patients with ectopic CS has been reported.

Conference:

Presenting Author:

Authors: González Devia D, Florez-Romero A, Rojas-Camacho J, Herrera Almario G, Jimenez Hakim E,

Keywords: ACTH-dependent Cushing's syndrome, Osilodrostat, Adrenal steroidogenesis inhibitors, Ectopic ACTH Cushing´s syndrome,